This Plain Language Summary of publication article (PLSP) from Future Oncology highlights findings from the CheckMate 9ER study, which evaluated the quality of life in people with advanced renal cell carcinoma (RCC) treated with cabozantinib plus nivolumab (CaboNivo) versus sunitinib. Participants completed questionnaires assessing cancer symptoms, treatment side effects, and overall health. The study measured both treatment effectiveness and how long it took for quality-of-life ratings to worsen.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial’  and was published in the Lancet Oncology.

Visit The Lancet using the link to read the original article.